Floatz logo

Pralatrexate

Systemic Anaplastic Large Cell Lymphoma

Corvus Pharmaceuticals, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Systemic Anaplastic Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Mingzhi Zhang
Phase 4BB
Crizotinib
Mingzhi Zhang
Phase 4BB
Inno-206
Huiqiang Huang
Phase 2BB
DEXAMETHASONE
Huiqiang Huang
Phase 2BB
Cyclophosphamide
Huiqiang Huang
Phase 2BB

View all 33 →

Same molecule, other indications

Pralatrexate is also rated in:

peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
74 / 100
View asset →
angioimmunoblastic T-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Nodal Peripheral T-Cell Lymphoma With TFH PhenotypeDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →